Studies show that biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C exhibit biological variability, raising concerns about their reliability in distinguishing AKI from CKD progression [17]. The gene discussed is CST3; the disease is chronic kidney disease.